


E1 1 175136-87-5/RN
 E2 1 175136-88-6/RN
 E3 1 --> 175136-89-7/RN
 E4 1 175136-90-0/RN
 E5 1 175136-91-1/RN
 E6 1 175136-92-2/RN
 E7 1 175136-93-3/RN
 E8 1 175136-94-4/RN
 E9 1 175136-95-5/RN
 E10 1 175136-96-6/RN
 E11 1 175136-97-7/RN
 E12 1 175136-98-8/RN

=> s e3

L1 1 175136-89-7/RN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
 RN 175136-89-7 REGISTRY
 CN Benzenemethanamine, 2-chloro-6-phenoxy- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-Aminomethyl-3-chlorodiphenyl ether
 CN 2-Chloro-6-phenoxybenzylamine
 FS 3D CONCORD
 MF C13 H12 Cl N O
 SR CAS Registry Services
 LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.08	2.29

FILE 'REGISTRY' ENTERED AT 16:25:19 ON 01 APR 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2003 HIGHEST RN 501072-24-8
 DICTIONARY FILE UPDATES: 31 MAR 2003 HIGHEST RN 501072-24-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

09845992

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

46.19

194.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-6.51

-6.51

STN INTERNATIONAL LOGOFF AT 09:05:22 ON 04 FEB 2003

09845992

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1626kas

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX,

Kamal Saeed

09845992

ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:03:32 ON 04 FEB 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:03:40 ON 04 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 FEB 2003 HIGHEST RN 484639-64-7

DICTIONARY FILE UPDATES: 2 FEB 2003 HIGHEST RN 484639-64-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

Kamal Saeed

09845992

=>

Uploading C:\Program Files\Stnexp\Queries\0984599211.str

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d

L2 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> s l1 full

FULL SEARCH INITIATED 09:04:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2182 TO ITERATE

100.0% PROCESSED 2182 ITERATIONS

33 ANSWERS

SEARCH TIME: 00.00.01

L3 33 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 09:04:23 ON 04 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

Kamal Saeed

09845992

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Feb 2003 VOL 138 ISS 6

FILE LAST UPDATED: 3 Feb 2003 (20030203/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 10 L3

=> d ibib abs hitstr tot

09845992


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:925264 CAPLUS
 DOCUMENT NUMBER: 138:11431
 TITLE: 5-HT1a antagonist or an .alpha.2-adrenergic antagonist
 in combination with an serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea
 INVENTOR(S): Howard, Harry Ralph, Jr.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1262197	A2	20021204	EP 2002-253589	20020522
EP 1262197	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002183306	A1	20021205	US 2002-75849	20020213
JP 2003026602	A2	20030129	JP 2002-155222	20020529
OTHER SOURCE(S): MARPAT 138:11431				


AB The invention provides a method of treating sleep disorders, including sleep apnea, in a mammal, including a human, by administering to the mammal a 5-HT1a antagonist or an .alpha.2-adrenergic antagonist in combination with an serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in efficacy. Also provided are pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT1a antagonist or an .alpha.2-adrenergic antagonist, and an SRI antidepressant agent.

IT 289716-94-5 289717-18-6 289717-57-3
 289717-60-8 289717-61-9 289717-67-5
 289717-68-6 289717-71-1 289717-72-2
 444888-21-5 444888-23-7 444888-24-8
 444888-49-7 477337-55-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (5-HT1a antagonist or .alpha.2-adrenergic antagonist in combination with serotonin reuptake inhibitor for treatment of sleep disorders, including sleep apnea)
 RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-18-6 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS
 CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-67-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 289717-68-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 289717-71-1 CAPLUS
 CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-72-2 CAPLUS
 CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 444888-21-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-.alpha.-trimethyl- (9CI) (CA INDEX NAME)




RN 444888-23-7 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)





09845992


L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 444888-24-8 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 444888-49-7 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 477337-55-6 CAPLUS
 CN Benzenemethanamine, 5-fluoro-2-(4-fluoro-3-methoxyphenoxy)-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 for use in alcoholism and alc. dependence)
 RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-18-6 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-57-3 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:925263 CAPLUS
 DOCUMENT NUMBER: 138:336
 TITLE: Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
 INVENTOR(S): Howard, Harry Ralph, Jr.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 37 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1262196	A2	20021204	EP 2002-253105	20020502
EP 1262196	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002370975	A2	20021224	JP 2002-132804	20020508
AU 2002040686	A5	20021205	AU 2002-40686	20020516
CN 1386503	A	20021225	CN 2002-120350	20020523
PRIORITY APPLN. INFO.: US 2001-293088 P 20010523				
OTHER SOURCE(S): MARPAT 138:336				

GI




AB The present invention relates to a method of treating alcoholism or alc. dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist. An example monoamine reuptake inhibitor is I.
 IT 289716-94-5 289717-18-6 289717-24-4
 289717-57-3 289717-58-4 289717-60-8
 289717-61-9 289717-67-5 289717-68-6
 289717-71-1 289717-72-2
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of a monoamine reuptake inhibitor and an opioid antagonist)


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-58-4 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-60-8 CAPLUS
 CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)


Kamal Saeed

09845992


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
Rotation (+).

RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2002:904325 CAPLUS
DOCUMENT NUMBER: 137:380038
TITLE: Combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety
INVENTOR(S): Howard, Harry Ralph, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1260221	A2	20021127	EP 2002-253135	20020503
EP 1260221	A3	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2002040681	A5	20021205	AU 2002-40681	20020516
JP 2002370976	A2	20021224	JP 2002-141515	20020516
CN 1386504	A	20021225	CN 2002-120351	20020523
PRIORITY APPLN. INFO.: US 2001-293063 P 20010523				
OTHER SOURCE(S): MARPAT 137:380038				
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.				
IT 289716-94-5 289717-18-6 289717-24-4 289717-57-3 289717-58-4 289717-60-8 289717-61-9 289717-67-5 289717-68-6 289717-71-1 289717-72-2				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(monoamine reuptake inhibitor; combination treatment with monoamine reuptake inhibitor and dopamine D3 receptor agonist for monoamine reuptake inhibitor and dopamine D3 receptor agonist for depression and anxiety)				
RN 289716-94-5 CAPLUS				
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)				




RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)


Kamal Saeed

09845992

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:755211 CAPLUS
DOCUMENT NUMBER: 137:262839
TITLE: Preparation of phenoxybenzylamines as monoamine reuptake inhibitors for treatment of CNS disorders.
INVENTOR(S): Howard, Harry R.; Schmidt, Christopher J.; Seeger, Thomas F.; Elliott, Mark L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 529,207.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002143003	A1	20021003	US 2001-845992	20010430
WO 2000050380	A1	20000831	WO 2000-1B108	20000202

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1999-121313P P 19990223
US 2000-529207 A2 20000202
WO 2000-1B108 W 20000202


OTHER SOURCE(S): MARPAT 137:262839
AB ROZCR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclyl; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prepd. as monoamine reuptake inhibitors (no data). Such compds. are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

IT 289716-89-8P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride 289716-93-4P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride 289716-94-5P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride 289716-95-6P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-18-6P, Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- 289717-19-7P, Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-23-3P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-24-4P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- 289717-25-5P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (2Z)-2-butenedioate (1:1) 289717-26-6P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, hydrochloride 289717-28-8P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) 289717-35-7P, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-,

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)


hydrochloride 289717-36-8P, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride 289717-57-3P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- 289717-58-4P, Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- 289717-60-8P, Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- 289717-61-9P, Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- 289717-67-5P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- 289717-68-6P, Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- 289717-71-1P, Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- 289717-72-2P, Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 289716-89-8 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-93-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Kamal Saeed

09845992

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289716-95-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-,
(2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289716-94-5
CMF C14 H12 Cl2 F N O




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-18-6 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-19-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-18-6
CMF C14 H12 Cl3 N O



CM 2
CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 289717-23-3 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1
CRN 289717-22-2
CMF C14 H12 Cl2 F N O

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N, .alpha.-dimethyl-,
(9CI) (CA INDEX NAME)




RN 289717-25-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N, .alpha.-dimethyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-24-4
CMF C15 H14 Cl2 F N O

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 289717-26-6 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N, .alpha.-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-28-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-,
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 289717-27-7
CMF C14 H12 Cl2 F N O

09845992


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CRN 110-16-7
CMP C4 H4 O4

Double bond geometry as shown.




RN 289717-35-7 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289717-36-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl

RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



IT 289718-10-1P, Benzamide, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)
RN 289718-10-1 CAPLUS
CN Benzamide, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

09845992

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




App 17a

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:674788 CAPLUS
 DOCUMENT NUMBER: 137:195595
 TITLE: Atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis
 INVENTOR(S): Howard, Harry R., Jr.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 20 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002123490	A1	20020905	US 2001-10651	20011206
EP 1238676	A1	20020911	EP 2002-25153	20020220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002308801	A2	20021023	JP 2002-50579	20020227
PRIORITY APPL. INFO.: US 2001-272619P P 20010301				
OTHER SOURCE(S): MARPAT 137:195595				
AB The invention provides a method for treating depression, obsessive compulsive disorder, and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also provides pharmaceutical compns. contg. a pharmaceutically acceptable carrier, an atypical antipsychotic, and a serotonin reuptake inhibitor.				
IT 289716-94-5 289717-18-6 289717-24-4 289717-57-3 289717-58-4 289717-60-8 289717-61-9 289717-67-5 289717-68-6 289717-71-1 289717-72-2 444888-21-5 444888-23-7 444888-24-8 444888-30-6 444888-49-7				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(atypical antipsychotic-antidepressant combination for treatment of depression, obsessive compulsive disorder, and psychosis)				
RN 289716-94-5 CAPLUS				
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)				




RN 289717-18-6 CAPLUS

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-24-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-57-3 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 289717-60-8 CAPLUS
 CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-67-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 289717-68-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).


Kamal Saeed

09845992


L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 444888-21-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)


L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 444888-23-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




RN 444888-24-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI)
(CA INDEX NAME)





RN 444888-30-6 CAPLUS
CN Benzenemethanamine, 5-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI)
(CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 444888-49-7 CAPLUS
CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI)
(CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:595509 CAPLUS
DOCUMENT NUMBER: 137:135106
TITLE: Combination of a 5-HT3 receptor antagonist with a serotonin reuptake inhibitor for the treatment of depression
INVENTOR(S): Howard, Harry R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002107244	A1	20020808	US 2001-2303	20011102
EP 1230921	A1	20020814	EP 2002-250541	20020128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002275097	A2	20020925	JP 2002-20186	20020129
BR 2002000246	A	20021029	BR 2002-246	20020131
PRIORITY APPLN. INFO.:			US 2001-266340P	20010202

OTHER SOURCE(S): MARPAT 137:135106
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with a serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in sexual function and/or redn. in gastro-intestinal side effects. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant. The ratio of the 5-HT3 receptor antagonist and the SRI antidepressant agent is between 0.001 to 1 and 1000 to 1, and esp. between 0.01 to 1 and 100 to 1 (no data).

IT 289716-94-5 289717-18-6 289717-24-4
289717-57-3 289717-58-4 289717-60-8
289717-61-9 289717-67-5 289717-68-6
289717-71-1 289717-72-2 444888-21-5
444888-23-7 444888-24-8 444888-30-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of 5-HT3 receptor antagonist with serotonin reuptake inhibitor for treatment of depression)


RN 289716-94-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI)
(CA INDEX NAME)




Kamal Saeed

09845992


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 289717-18-6 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-24-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 289717-57-3 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI)
 (CA INDEX NAME)

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-68-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 289717-71-1 CAPLUS
 CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
 (CA INDEX NAME)




RN 289717-72-2 CAPLUS
 CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI)
 (CA INDEX NAME)


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289717-60-8 CAPLUS
 CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-61-9 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-67-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).


L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 444888-21-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, trimethyl- (9CI) (CA INDEX NAME)



RN 444888-23-7 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI)
 (CA INDEX NAME)




RN 444888-24-8 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)





Kamal Saeed

09845992

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 444888-30-6 CAPLUS
 CN Benzenemethanamine, 5-chloro-2-(3,4-dichlorophenoxy)-.alpha.-ethyl-N-methyl- (9CI) (CA INDEX NAME)





RN 444888-49-7 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:171851 CAPLUS
 DOCUMENT NUMBER: 136:232110
 TITLE: Preparation of phenoxybenzylamines as selective serotonin re-uptake inhibitors
 INVENTOR(S): Adam, Mavis Diane; Andrews, Mark David; Elliott, Mark Leonard; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018333	A1	20020307	WO 2001-1B1521	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001078650	A5	20020313	AU 2001-78650	20010822
PRIORITY APPLN. INFO.: GB 2000-21593 A 20000831 GB 2001-7116 A 20010321 WO 2001-1B1521 W 20010822				
OTHER SOURCE(S): MARPAT 136:232110				
GI				



AB Title compds. I [R1 and R2 independently = H, alkyl or

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (CH2)n(C3-C6cycloalkyl) wherein n = 0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached from an azetidine ring; Z or Y is -SR3 and the other Z or Y is halogen or -R3; wherein R3 = C1-4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein
 when Z and Y form a heterocyclic ring, in addn. to carbon atoms, the linkage contains one or two heteroatoms independently selected from O, S and N; R4 and R5 independently = A-X, wherein A = -CH=CH- or -(CH2)p- where p is 0, 1 or 2; X = H, halo, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, Cl-alkoxy, etc; or A-X = (un)substituted 5- or 6-membered heterocyclic ring contg. 1, 2 or 3 heteroatoms selected from N, S and O; R6 and R7 independently = H, (un)substituted alkyl; or R6 and R7 together with the


N to which they are attached form a (un)substituted 4-6 membered heterocyclic ring) and there pharmaceutically acceptable salts are prepd. Thus, II was prepd. via substitution of 5-(aminosulfonyl)-2-fluoro-N-methylbenzamide by 2,3-dihydrobenzo[b]thiophen-5-ol with successive BF3.cntdot.THF catalyzed amide redn., formylation of secondary amine, and redn. II demonstrated a serotonin re-uptake inhibition IC50 of 4.7nM. I inhibit monoamine re-uptake and in particular exhibit activity as selective serotonin reuptake inhibitors.

IT 402910-54-7P 402910-56-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402910-54-7 CAPLUS

CN Benzenemethanamine, 5-bromo-2-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 402910-56-9 CAPLUS

CN Benzenemethanamine, 5-bromo-2-[3-chloro-4-(methylthio)phenoxy]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

09845992

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:816609 CAPLUS
 DOCUMENT NUMBER: 135:344284
 TITLE: Process for the preparation of 2-halobenzoic acids by palladium-catalyzed regioselective halogenation of benzoic acids
 INVENTOR(S): Kodama, Hiroki; Katsuhira, Takeshi; Nishida, Tateki; Hino, Tomokazu; Teubata, Kenji
 PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083421	A1	20011108	WO 2001-JP3707	20010427
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001052638	A5	20011112	AU 2001-52638	20010427
EP 1277726	A1	20030122	EP 2001-926032	20010427
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2002338516	A2	20021127	JP 2001-134049	20010501
PRIORITY APPLN. INFO.:			JP 2000-131032	A 20000428
			JP 2001-76073	A 20010316
			WO 2001-JP3707	W 20010427
OTHER SOURCE(S):		CASREACT 135:344284; MARPAT 135:344284		
GI				



AB A process for the prepn. of 2-halobenzoic acids of the general formula [I];
 A is OH, OM (wherein M is an alkali metal), or NR6R7 (wherein R6 and R7 are each H, C1-6 alkyl, optionally substituted Ph, or the like); R is H,


L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:283913 CAPLUS
 DOCUMENT NUMBER: 134:310974
 TITLE: Preparation of biaryl ether derivatives as monoamine reuptake inhibitors
 INVENTOR(S): Howard, Harry Ralph, Jr.; Adam, Mavis Diane
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027068	A1	20010419	WO 2000-1B1373	20000927
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000014733	A	20020611	BR 2000-14733	20000927
EP 1220831	A1	20020710	EP 2000-960916	20000927
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6410736	B1	20020625	US 2000-692335	20001019
NO 2002001659	A	20020408	NO 2002-1659	20020408
PRIORITY APPLN. INFO.:			US 1999-159276P	P 19991013
			US 1999-167761P	P 19991129
			WO 2000-1B1373	W 20000927
OTHER SOURCE(S):		MARPAT 134:310974		
GI				




AB The title compds. [I; rings A and B can be replaced by naphthyl group; n, m = 1-3; R1, R2 = H, alkyl, alkenyl, etc.; NR1R2 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R1 and R2 are attached; R3, R4 = H, alkyl optionally substituted with 1-3 F

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 C1-6 alkyl, C1-6 alkylcarbonyl, carbonyl, C1-12 alkoxy, carbonyl, optionally substituted phenylcarbonyl, or the like; n is 0 to 4; and X is Cl, Br, or iodo, or alternatively NR's may be present on benzene-constituting carbon atoms adjacent to each other and form a C3-4 alkylene or C3-4 alkenylene-fused ring.) is characterized by reacting a benzoic acid of the general formula I (X = H; A, R, n = same as above) with a halogenating agent in the presence of a Pd catalyst. This process provides regioselective halogenation under mild conditions. Thus, 0.3 g o-toluic acid, 0.5 g N-iodosuccinimide, and 11 mL DMF were added to 50 mg Pd(OAc)2 in a 50 mL glass reaction vessel and stirred at 100.degree. for 6 h to give 92% 2-iodo-6-methylbenzoic acid with 100% regioselectivity.
 IT 371771-35-6P, 2-(4-Chloro-2-methylphenoxy)-N-(1,1-dimethyl-2-methylthioethyl)-6-iodobenzamide
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of 2-halobenzoic acids by regioselective halogenation of benzoic acids in presence of palladium compd.)
 RN 371771-35-6 CAPLUS
 CN Benzanide, 2-(4-chloro-2-methylphenoxy)-N-[1,1-dimethyl-2-(methylthio)ethyl]-6-iodo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 NR2CR3 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R2 is attached; X = (un)substituted Ph, heteroaryl, heterocyclyl; Y = H, halo, alkyl optionally substituted with 1-3 F atoms, etc.; Z = H, halo, alkoxy, etc.) and their pharmaceutically acceptable salts which exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders, were prepd. E.g., a 3-step synthesis of I [R1 = Me; R2-R4 = H; X = 5-Ph; Z = H; Y = 3,4-Cl2] was given. All exemplified compds. I showed IC50 of .ltoreq. 250 nM for serotonin reuptake inhibition, and IC50 of .ltoreq. 1000 nM for dopamine and for norepinephrine reuptake inhibition.
 IT 289717-61-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of biaryl ether derivs. as monoamine reuptake inhibitors)
 RN 289717-61-9 CAPLUS
 CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

Kamal Saeed

09845992


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:608708 CAPLUS
 DOCUMENT NUMBER: 133:207665
 TITLE: Preparation of phenoxybenzylamines as monoamine reuptake inhibitors
 INVENTOR(S): Elliott, Mark Leonard; Howard, Harry Ralph, Jr.; Schmidt, Christopher Joseph; Seeger, Thomas Francis
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050380	A1	20000831	WO 2000-1B108	20000202
<p>W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RM: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG</p> <p>EP 1154984 A1 20011121 EP 2000-900785 20000202</p> <p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO</p> <p>BR 2000008958 A 20011127 BR 2000-8958 20000202</p> <p>US 2002143003 A1 20021003 US 2001-845992 20010430</p> <p>NO 2001004047 A 20011022 NO 2001-4047 20010820</p> <p>PRIORITY APPLN. INFO.: US 1999-121313P P 19990223</p> <p>US 2000-529207 A2 20000202</p> <p>WO 2000-1B108 W 20000202</p>				
OTHER SOURCE(S): MARPAT 133:207665				
GI				



AB R02CR3R4NR1R2 [R = (un)substituted Ph; R1,R2 = H, alk(en)yl, alkynyl; NR1R2 = heterocyclyl; R3,R4 = H or (fluoro)alkyl; R3R4 = (un)substituted alkylene; R2R3 = atoms to complete a heterocyclic ring; Z = (un)substituted phenylene] were prep. as monoamine reuptake inhibitors (no data). Thus, 2,5-F(F3C)C6H3CHO was aroxyated by 3,4-Cl2C6H3OH and


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 289716-95-6 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, (2Z)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289716-94-5
 CMP C14 H12 Cl2 F N O




CM 2

CRN 110-16-7
 CMP C4 H4 O4

Double bond geometry as shown.




RN 289717-18-6 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
 the product reductively aminated by Me2NH to give title comp. I.
 IT 289716-89-8P 289716-93-4P 289716-94-5P
 289716-95-6P 289717-18-6P 289717-19-7P
 289717-23-3P 289717-24-4P 289717-25-5P
 289717-26-6P 289717-28-8P 289717-35-7P
 289717-36-8P 289717-37-9P 289717-58-4P
 289717-60-8P 289717-61-9P 289717-67-5P
 289717-68-6P 289717-71-1P 289717-72-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)
 RN 289716-89-8 CAPLUS
 CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 289716-93-4 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 289716-94-5 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 289717-19-7 CAPLUS
 CN Benzenemethanamine, 4-chloro-2-(3,4-dichlorophenoxy)-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-18-6
 CMP C14 H12 Cl3 N O



CM 2

CRN 110-16-7
 CMP C4 H4 O4


Double bond geometry as shown.



RN 289717-23-3 CAPLUS
 CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-3-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-22-2
 CMP C14 H12 Cl2 F N O



CM 2


CRN 110-16-7

Kamal Saeed


09845992

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
CMP C4 H4 O4

Double bond geometry as shown.




RN 289717-24-4 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 289717-25-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 289717-24-4
CMF C15 H14 Cl2 F N O




CM 2

CRN 110-16-7
CMF C4 H4 O4

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-35-7 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-36-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-57-3 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-58-4 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl- (9CI)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
Double bond geometry as shown.



RN 289717-26-6 CAPLUS
CN Benzenemethanamine, 2-(4-chlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 289717-28-8 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-4-fluoro-N-methyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 289717-27-7
CMF C14 H12 Cl2 F N O




CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.


L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)



RN 289717-60-8 CAPLUS
CN Benzenemethanamine, 4-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 289717-61-9 CAPLUS
CN Benzenemethanamine, 5-bromo-2-(3,4-dichlorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-67-5 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).


09845992

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 289717-68-6 CAPLUS
CN Benzenemethanamine, 2-(3,4-dichlorophenoxy)-5-fluoro-N,.alpha.-dimethyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 289717-71-1 CAPLUS
CN Benzenemethanamine, 2-(4-chloro-3-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 289717-72-2 CAPLUS
CN Benzenemethanamine, 2-(3-chloro-4-fluorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 289718-10-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenoxybenzylamines as monoamine reuptake inhibitors)
RN 289718-10-1 CAPLUS
CN Benzamide, 2-(3,4-dichlorophenoxy)-5-fluoro-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT